Abnormal Fluctuation Statistics of HKEX Connect | May 7

Zhitong HK Stock Connect Proportion Change Statistics | May 6, 2026

Zhitong FinanceMay 7 08:36

Baoji Pharmaceutical-B (02659.HK) is not aware of any reasons for the abnormal fluctuations in the H-share price and trading volume. The controlling shareholder intends to increase its shareholding and plans to propose a share repurchase authorization.

Gelonghui, May 3rd ┃ Baoji Pharmaceutical-B (02659.HK) announced that the company's board of directors has noticed abnormal fluctuations in the price and trading volume of the company’s H shares recently. After conducting reasonable inquiries regarding the company under the relevant circumstances, the board confirmed that it is not aware of (i) any reasons causing the abnormal fluctuations in the H share price and trading volume; or (ii) any information that needs to be disclosed to avoid creating a false market for the company’s securities; or (iii) any insider information required to be disclosed under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board also confirmed.

Gelonghui FinanceMay 3 19:01

Baoji Pharmaceutical-B (02659) plans to have its Board Chairman, Dr. Liu Yanjun, increase his shareholding.

Baoji Pharmaceutical-B (02659) announced that the company has received a notice from Dr. Liu Yanjun, Chairman of the Board and member of the controlling shareholder group of the company, stating that based on his confidence in the prospects and growth potential of the group, as well as his recognition of the long-term investment value of the company, he intends to increase his holdings of the company's shares through open market transactions within three months from the date of this announcement. In accordance with the relevant minimum public float requirements under the Listing Rules, and to ensure the company’s continued compliance with such provisions, the maximum number of shares the controlling shareholder may acquire shall not exceed 38,893,900 H shares.

Zhitong FinanceMay 3 18:57

Baoji Pharmaceutical (02659.HK) Plummets 64% on Heavy Trading; Included in Shanghai-Hong Kong Stock Connect in Early March

Baoji Pharma-B (02659.HK), which was listed in December of last year, opened 0.4% lower this morning (August 30) with the decline rapidly widening. The stock closed at HKD 26.92 in the afternoon session, falling by 64.06%. Trading volume surged to 24.2661 million shares, involving a total value of HKD 739 million. The company is a biotechnology firm focusing on large-volume subcutaneous drug delivery, antibody-mediated autoimmune diseases, assisted reproductive technology, and recombinant biopharmaceuticals. It was officially included in the Hong Kong Stock Connect program on March 9 this year. Market analysts noted that Baoji Pharma experienced an astonishing surge shortly after its listing, reaching HKD 206 at the end of February this year, representing an accumulated increase of 6.8 times compared to its IPO price of HKD 26.38; as

AASTOCKSApr 30 15:52

Baoji Pharmaceuticals plunged over 64% in a flash crash, hitting a record low in the Hong Kong stock market. The company's market value has evaporated by HKD 58.5 billion in just two months.

Gelonghui, April 30 | The stock price of Baoji Pharmaceutical-B (2659.HK), which was listed in mid-December last year, plummeted by over 64% to HKD 26.38 in the afternoon trading session today, hitting a record low. Its market value dropped to HKD 8.6 billion, representing an erosion of HKD 58.5 billion from its peak on February 25, meaning that 87% of its market value has evaporated in just two months. According to the company's financial results released in March, revenue for the fiscal year 2025 reached RMB 49.156 million, a year-on-year increase of 700%; gross profit amounted to RMB 43.751 million, reflecting a year-on-year surge of 772%; while the loss attributable to owners of the parent company widened to RMB 395 million from RMB 364 million in the same period last year. Baoji Pharmaceutical.

Gelonghui FinanceApr 30 14:00

BAO PHARMA-B: 2025 ANNUAL REPORT

HKEXApr 27 19:00 · Announcements